{"i": ["Interferon Beta", "Atorvastatin"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["atorvastatin", "interferon beta - 1b ( IFNB - 1b )"], "o": []}
{"i": ["RRMS", "IFNB - 1b"], "o": []}
{"i": ["atorvastatin", "IFNB - 1b"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["proportion of patients with new lesions on T2 - weighted images"]}
{"i": [], "o": ["number of new lesions and total lesion volume on T2 - weighted images , total number of Gd - enhancing lesions on T1 - weighted images , volume of grey and white matter , EDSS , MSFC , relapse rate , number of relapse - free patients and neutralizing antibodies"]}
{"i": [], "o": []}
{"i": ["IFNB - 1b", "Atorvastatin"], "o": []}
{"i": [], "o": []}
{"i": ["atorvastatin", "interferon beta - 1b ( IFNB - 1b )"], "o": []}
{"i": ["RRMS", "IFNB - 1b"], "o": []}
{"i": ["atorvastatin", "IFNB - 1b"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["proportion of patients with new lesions on T2 - weighted images"]}
{"i": [], "o": ["number of new lesions and total lesion volume on T2 - weighted images , total number of Gd - enhancing lesions on T1 - weighted images , volume of grey and white matter , EDSS , MSFC , relapse rate , number of relapse - free patients and neutralizing antibodies"]}
{"i": [], "o": []}
{"i": ["IFNB - 1b", "Atorvastatin"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["statins"], "o": []}
{"i": ["atorvastatin", "subcutaneous IFNB - 1b", "subcutaneous interferon beta - 1b ( IFNB - 1b )", "Atorvastatin"], "o": ["efficacy , safety and tolerability"]}
{"i": ["atorvastatin", "IFNB - 1b", "IFNB", "statins"], "o": []}
{"i": ["IFNB", "statins"], "o": []}
{"i": [], "o": []}
{"i": ["Statin", "IFNB - 1a", "RRMS", "IFNB + statin"], "o": []}
{"i": ["IFNB - 1b"], "o": []}
{"i": ["IFNB + atorvastatin", "atorvastatin80"], "o": ["Gd - enhancing lesions"]}
{"i": ["IFNB + placebo", "IFNB - 1a", "IFNB + statin", "placebo"], "o": []}
{"i": ["atorvastatin"], "o": ["MRI and clinical disease activity"]}
{"i": ["atrovastatin or simvastatin", "IFNB - 1a", "IFNB + statin", "IFNB"], "o": ["relapse rate"]}
{"i": ["IFNB - 1a", "IFNB + statin", "IFNB"], "o": []}
{"i": ["atorvastatin", "atorvastatin20"], "o": ["relapses", "Gd \u2212 enhancing lesions"]}
{"i": ["simvastatin", "IFNB + simvastatin", "IFNB - 1a", "simvastatin40", "IFNB + placebo"], "o": ["relapse rate"]}
{"i": ["placebo - controlled", "IFNB - 1a", "IFNB + statin", "IFNB + placebo", "simvastatin80"], "o": ["relapse rate"]}
{"i": ["IFNB + statin", "IFNB - 1b", "IFNB"], "o": []}
{"i": ["atorvastatin40", "IFNB + statin", "IFNB - 1b", "IFNB"], "o": ["new T2 - lesions"]}
{"i": ["atorvastatin40"], "o": ["number ; IFNB , interferon beta", "new T2 - lesions"]}
{"i": ["atorvastatin", "IFNB - 1b"], "o": []}
{"i": [], "o": []}
{"i": ["mitoxantrone", "IFNB or glatiramer acetate"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["IFNB - 1b ( Betaferon \u00ae/ Betaseron"], "o": []}
{"i": ["atorvastatin", "not in addition to IFNB - 1b"], "o": []}
{"i": ["atorvastatin"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["atorvastatin"], "o": []}
{"i": ["Placebo"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["atorvastatin"], "o": []}
{"i": [], "o": ["proportion of patients with new lesions on T2 - weighted MR images ."]}
{"i": [], "o": ["number of new lesions on T2 - weighted images , change in total lesion volume on T2 - weighted images ( burden of disease ), total number of gadolinium ( Gd \u2212) enhancing lesions on T1 - weighted images , changes in volume of grey and white matter , clinical disease progression ( EDSS , MSFC ), relapse rate , time to first relapse , number of relapse - free patients , and neutralizing antibodies ( NAbs )."]}
{"i": [], "o": ["Adverse events ( AE ), laboratory data , vital signs and concomitant medication"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["EDSS , MSFC , neutralizing antibodies ( NAbs ), brain MRI", "efficacy and safety"]}
{"i": [], "o": []}
{"i": ["Atorvastatin"], "o": []}
{"i": ["atorvastatin"], "o": []}
{"i": [], "o": ["total EDSS score"]}
{"i": [], "o": ["Fatigue , mental and / or vegetative symptoms"]}
{"i": ["oral prednisolone .", "intravenous methylprednisolone"], "o": []}
{"i": ["Atorvastatin"], "o": ["transaminases"]}
{"i": ["atorvastatin"], "o": ["liver enzymes"]}
{"i": [], "o": []}
{"i": ["T1 - weighted axial spin - echo , T1 - weighted sagittal 3D MPRAGE , axial dual - echo i . e ."], "o": []}
{"i": ["proton - density , T2 - weighted turbo - spin - echo images", "Gd - injection", "axial T1 - weighted spin - echo images"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["neutralisation titre"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["proportion of patients with new T2 lesions"]}
{"i": [], "o": []}
{"i": [], "o": ["number of T2 lesions , number of Gd - enhancing lesions , EDSS , relapse rate and time since MS diagnosis"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["Time to first relapse"]}
{"i": [], "o": ["safety and tolerability variables"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["IFNB", "statins"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["atorvastatin / IFNB - 1b", "IFNB - 1b"], "o": []}
{"i": [], "o": []}
{"i": ["atorvastatin"], "o": []}
{"i": ["atorvastatin"], "o": ["compliance"]}
{"i": ["atorvastatin"], "o": []}
{"i": [], "o": []}
{"i": ["Atorvastatin / Interferon"], "o": []}
{"i": [], "o": []}
{}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["Total volume of T2 hyperintense lesions"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["Expanded Disability Status Scale"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{}
{"i": [], "o": []}
{"i": ["atorvastatin / IFNB - 1b", "IFNB - 1b"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["atorvastatin / IFNB - 1b", "IFNB - 1b"], "o": []}
{"i": [], "o": ["Change in lesion volume"]}
{"i": ["atorvastatin / IFNB - 1b", "IFNB - 1b"], "o": []}
{"i": [], "o": ["Total number of Gd - enhancing T1 - lesions"]}
{"i": ["atorvastatin / IFNB - 1b", "IFNB - 1b"], "o": []}
{"i": [], "o": ["Change of grey matter volume"]}
{"i": [], "o": []}
{"i": [], "o": ["Change of white matter volume"]}
{"i": [], "o": []}
{"i": [], "o": ["grey and white matter volume"]}
{"i": [], "o": []}
{"i": [], "o": []}
{}
{"i": [], "o": ["EDSS score"]}
{"i": [], "o": []}
{"i": [], "o": ["MSFC score"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["atorvastatin / IFNB - 1b", "IFNB - 1b"], "o": ["Relapse - free"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["atorvastatin / IFNB - 1b", "IFNB - 1b"], "o": []}
{"i": [], "o": ["proportion of patients with new lesions on T2 -"]}
{"i": ["atorvastatin / IFNB - 1b", "IFNB - 1b"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["number of new lesions and total lesion volume on T2 - weighted images , total number of Gd - enhancing lesions on T1 - weighted images , volume of grey and white matter , EDSS , MSFC ( including subscores ), relapse rate , number of relapse - free patients and NAb"]}
{"i": [], "o": ["time to next relapse"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["atorvastatin / IFNB - 1b"], "o": ["number of new lesions on T2 - weighted images and total number of Gd - enhancing lesions"]}
{"i": [], "o": ["total number of Gd - enhancing lesions on T1", "number of Gd - enhancing lesions", "new lesions on T2 - weighted images , total number of Gd - enhancing lesions on T1 - weighted images , EDSS , relapse rate , gender , disease duration"]}
{"i": [], "o": []}
{"i": [], "o": ["AEs including serious and severe AEs"]}
{"i": [], "o": []}
{"i": ["atorvastatin / IFNB - 1b"], "o": ["influenza - like illness and increased hepatic enzymes"]}
{"i": ["atorvastatin / IFNB - 1b"], "o": ["Elevated liver enzymes"]}
{"i": ["atorvastatin / IFNB - 1b"], "o": []}
{"i": [], "o": ["severe or serious AE ."]}
{"i": ["IFNB - 1b"], "o": ["AEs", "foot fracture"]}
{"i": [], "o": []}
{"i": ["Atorvastatin /"], "o": []}
{"i": [], "o": ["Total number of adverse events"]}
{"i": [], "o": []}
{"i": [], "o": ["Adverse events ( AE"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["serious AE"]}
{"i": [], "o": []}
{"i": [], "o": ["Injury , poisoning and procedural complications"]}
{"i": ["IFNB - 1b", "Atorvastatin"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["atorvastatin and IFNB - 1b"], "o": ["severe side effects ."]}
{"i": [], "o": []}
{"i": ["atorvastatin", "atorvastatin / IFNB - 1b"], "o": ["elevated liver enzymes"]}
{"i": ["statins and IFNB"], "o": []}
{"i": ["atorvastatin", "simvastatin"], "o": []}
{"i": ["IFNB", "atorvastatin or simvastatin"], "o": ["serious side effects", "safe and well tolerated"]}
{"i": ["atorvastatin", "IFNB - 1b"], "o": []}
{"i": [], "o": []}
{"i": ["IFNB", "statins"], "o": []}
{"i": ["atorvastatin and simvastatin"], "o": []}
{"i": ["atorvastatin", "simvastatin"], "o": []}
{"i": [], "o": []}
{"i": ["IFNB", "statins"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["statins"], "o": []}
{"i": ["Statins"], "o": []}
{"i": ["simvastatin"], "o": ["number and volume of Gd - enhancing lesions"]}
{"i": ["placebo - controlled", "simvastatin"], "o": ["brain atrophy measures", "relapse rate or T2 lesion activity"]}
{"i": ["statins"], "o": []}
{"i": ["statins"], "o": []}
{"i": ["statins"], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["number of patients"]}
{"i": ["IFNB", "statins"], "o": ["efficacy and safety"]}
{"i": ["placebo - controlled", "placebo"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["atorvastatin ."], "o": []}
{"i": ["atorvastatin"], "o": []}
{"i": [], "o": []}
{"i": ["atorvastatin ."], "o": []}
{"i": ["atorvastatin", "IFNB - 1b"], "o": []}
{"i": ["atorvastatin", "IFNB"], "o": []}
{"i": [], "o": ["side effects .", "tolerated and safe"]}
